My reply to the soft-bashing SA article (since, if
Post# of 72440
(Total Views: 350)
Posted On: 03/07/2017 9:09:59 AM
My reply to the soft-bashing SA article (since, if history is any clue to the future, SA will delete this soon):
Drrano
Comments (103) |
This article does not mention Brilacidin clinical trials for two non-antibiotic applications. Brilacidin has powerful anti-inflammatory properties, and these properties are being studied in clinical trials for ulcerative procitis, a debilitating lower GI tract condition, and for oral mucositis, a common side effect of chemotherapy for which there is currently no good treatment. Early results thus far of the Brilacidin-UP trials have been very positive. These trials will have more results very soon, and positive results will be a game-changer.
Cellceutix's attorney, Michael Sullivan of the Ashcroft Law Firm, is far more than a "fairly reputable attorney." He is the former U.S. Attorney for the District of Massachusetts. Here is his official biography:
http://bit.ly/2meKnWp
CTIX fought back against an article by avowed short-seller Mako, which contained many provably untrue statements, such as their claim that the offices were "empty." Federal Judge Failla of the Southern District of New York agreed that the claims in the article were completely unfounded, and that the Rosen Firm should not have filed a lawsuit against CTIX on the basis of this information -- which the company proved to be entirely untrue. It is important for people to understand that most companies do not fight these types of lawsuits, but instead pay a few hundred thousand dollars (often called "greenmail" ) because it is cheaper to pay a settlement than it is to pay lawyers to fight it. It is important to note that attorney Sullivan's law firm, "fairly reputable" former Attorney General of the United State's John Ashcroft's law firm, agreed to take warrants to buy Cellceutix stock at 1.70, as their payment. This is a tremendous vote of confidence in this company's management and its science.
Drrano
Comments (103) |
This article does not mention Brilacidin clinical trials for two non-antibiotic applications. Brilacidin has powerful anti-inflammatory properties, and these properties are being studied in clinical trials for ulcerative procitis, a debilitating lower GI tract condition, and for oral mucositis, a common side effect of chemotherapy for which there is currently no good treatment. Early results thus far of the Brilacidin-UP trials have been very positive. These trials will have more results very soon, and positive results will be a game-changer.
Cellceutix's attorney, Michael Sullivan of the Ashcroft Law Firm, is far more than a "fairly reputable attorney." He is the former U.S. Attorney for the District of Massachusetts. Here is his official biography:
http://bit.ly/2meKnWp
CTIX fought back against an article by avowed short-seller Mako, which contained many provably untrue statements, such as their claim that the offices were "empty." Federal Judge Failla of the Southern District of New York agreed that the claims in the article were completely unfounded, and that the Rosen Firm should not have filed a lawsuit against CTIX on the basis of this information -- which the company proved to be entirely untrue. It is important for people to understand that most companies do not fight these types of lawsuits, but instead pay a few hundred thousand dollars (often called "greenmail" ) because it is cheaper to pay a settlement than it is to pay lawyers to fight it. It is important to note that attorney Sullivan's law firm, "fairly reputable" former Attorney General of the United State's John Ashcroft's law firm, agreed to take warrants to buy Cellceutix stock at 1.70, as their payment. This is a tremendous vote of confidence in this company's management and its science.
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼